Skip to main content

Advertisement

SpringerLink
Log in

FOXD2-AS1 acts an oncogene in esophageal squamous cell carcinoma through sponging miR-204-3p

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

A growing number of evidences has revealed that long non-coding RNAs (lncRNAs) have vital effect in the pathogenesis of esophageal squamous cell carcinoma (ESCC). In our work, we found that lncRNA FOXD2 adjacent opposite strand RNA 1 (FOXD2-AS1) was significantly increased in clinical ESCC samples and cell lines.

Methods

The biological effect of FOXD2-AS1 on EC109 and KYSE150 cells showed that the low expression of FOXD2-AS1 inhibited the proliferation through CCK8 and colony formation assays, invasion by transwell chamber test, migration abilities by wound healing assay, and enhance apoptosis rates by flow cytometry assay.

Results

Through bioinformatics analysis and luciferase reporter assays, microRNA (miR)-204-3p was proved to be a target of FOXD2-AS1. We further confirmed that FOXD2-AS1 was the upstream inhibitor of miR-204-3p and the down-regulation of miR-204-3p reversed the repressive effects of low expression of FOXD2-AS1 on ESCC progression. In addition, inhibition of FOXD2-AS1 effectively suppressed the tumor growth.

Conclusions

In general, our results suggested that FOXD2-AS1 may be of vital therapeutic importance for the treatment of ESCC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Zheng Y, Chen Z, Han Y, Han L, Zou X, Zhou B, Hu R, Hao J, Bai S, Xiao H, Li WV, Bueker A, Ma Y, Xie G, Yang J, Chen S, Li H, Cao J, Shen L. Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment. Nat Commun. 2020;11:6268.

    Article  CAS  Google Scholar 

  2. Salem ME, Puccini A, Xiu J, Raghavan D, Lenz HJ, Korn WM, Shields AF, Philip PA, Marshall JL, Goldberg RM. Comparative molecular analyses of esophageal squamous cell carcinoma, esophageal adenocarcinoma, and gastric adenocarcinoma. Oncologist. 2018;23:1319–27.

    Article  CAS  Google Scholar 

  3. Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2014;371:2499–509.

    Article  Google Scholar 

  4. Kim M. Evaluation of a web-based app demonstrating an exclusionary algorithmic approach to TNM cancer staging. JMIR Cancer. 2015;1: e3.

    Article  Google Scholar 

  5. Zhang S, Qin C, Cao G, Xin W, Feng C, Zhang W. Systematic analysis of long noncoding RNAs in the senescence-accelerated mouse prone 8 brain using RNA sequencing. Mol Ther Nucleic Acids. 2016;5: e343.

    Article  CAS  Google Scholar 

  6. Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z, Deng X, Chen H, Shen B, Peng C, Li H, Zhan Q, Zhu Z. Amplification of long noncoding RNA ZFAS1 promotes metastasis in hepatocellular carcinoma. Cancer Res. 2015;75:3181–91.

    Article  CAS  Google Scholar 

  7. Li Z, Qin X, Bian W, Li Y, Shan B, Yao Z, Li S. Exosomal lncRNA ZFAS1 regulates esophageal squamous cell carcinoma cell proliferation, invasion, migration and apoptosis via microRNA-124/STAT3 axis. J Exp Clin Cancer Res. 2019;38:477.

    Article  CAS  Google Scholar 

  8. Wang J, Li B, Wang C, Luo Y, Zhao M, Chen P. Long noncoding RNA FOXD2-AS1 promotes glioma cell cycle progression and proliferation through the FOXD2-AS1/miR-31/CDK1 pathway. J Cell Biochem. 2019;120:19784–95.

    Article  CAS  Google Scholar 

  9. Ni W, Xia Y, Bi Y, Wen F, Hu D, Luo L. FoxD2-AS1 promotes glioma progression by regulating miR-185-5P/HMGA2 axis and PI3K/AKT signaling pathway. Aging (Albany NY). 2019;11:1427–39.

    Article  CAS  Google Scholar 

  10. Kang M, Ren M, Li Y, Fu Y, Deng M, Li C. Exosome-mediated transfer of lncRNA PART1 induces gefitinib resistance in esophageal squamous cell carcinoma via functioning as a competing endogenous RNA. J Exp Clin Cancer Res. 2018;37:171.

    Article  Google Scholar 

  11. Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77:3965–81.

    Article  CAS  Google Scholar 

  12. Dinescu S, Ignat S, Lazar AD, Constantin C, Neagu M, Costache M. Epitranscriptomic signatures in lncRNAs and their possible roles in cancer. Genes (Basel). 2019;10:52.

    Article  Google Scholar 

  13. Jiang M, Qiu N, Xia H, Liang H, Li H, Ao X. Long noncoding RNA FOXD2AS1/miR1505p/PFN2 axis regulates breast cancer malignancy and tumorigenesis. Int J Oncol. 2019;54:1043–52.

    CAS  PubMed  Google Scholar 

  14. Yang X, Duan B, Zhou X. Long non-coding RNA FOXD2-AS1 functions as a tumor promoter in colorectal cancer by regulating EMT and Notch signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21:3586–91.

    CAS  PubMed  Google Scholar 

  15. Xu TP, Wang WY, Ma P, Shuai Y, Zhao K, Wang YF, Li W, Xia R, Chen WM, Zhang EB, Shu YQ. Upregulation of the long noncoding RNA FOXD2-AS1 promotes carcinogenesis by epigenetically silencing EphB3 through EZH2 and LSD1, and predicts poor prognosis in gastric cancer. Oncogene. 2018;37:5020–36.

    Article  CAS  Google Scholar 

  16. Shi W, Gao Z, Song J, Wang W. Silence of FOXD2-AS1 inhibited the proliferation and invasion of esophagus cells by regulating miR-145-5p/CDK6 axis. Histol Histopathol. 2020;35:1013–21.

    CAS  PubMed  Google Scholar 

  17. Bao J, Zhou C, Zhang J, Mo J, Ye Q, He J, Diao J. Upregulation of the long noncoding RNA FOXD2-AS1 predicts poor prognosis in esophageal squamous cell carcinoma. Cancer Biomark. 2018;21:527–33.

    Article  CAS  Google Scholar 

  18. Liu H, Zhang J, Luo X, Zeng M, Xu L, Zhang Q, Liu H, Guo J, Xu L. Overexpression of the long noncoding RNA FOXD2-AS1 promotes cisplatin resistance in esophageal squamous cell carcinoma through the miR-195/Akt/mTOR axis. Oncol Res. 2020;28:65–73.

    Article  Google Scholar 

  19. Liang Y, Chen X, Wu Y, Li J, Zhang S, Wang K, Guan X, Yang K, Bai Y. LncRNA CASC9 promotes esophageal squamous cell carcinoma metastasis through upregulating LAMC2 expression by interacting with the CREB-binding protein. Cell Death Differ. 2018;25:1980–95.

    Article  CAS  Google Scholar 

  20. Zang B, Zhao J, Chen C. LncRNA PCAT-1 promoted ESCC progression via regulating ANXA10 expression by sponging miR-508-3p. Cancer Manag Res. 2019;11:10841–9.

    Article  CAS  Google Scholar 

  21. Tang Y, Yang P, Zhu Y, Su Y. LncRNA TUG1 contributes to ESCC progression via regulating miR-148a-3p/MCL-1/Wnt/beta-catenin axis in vitro. Thorac Cancer. 2020;11:82–94.

    Article  CAS  Google Scholar 

  22. Ren P, Zhang H, Chang L, Hong XD, Xing L. LncRNA NR2F1-AS1 promotes proliferation and metastasis of ESCC cells via regulating EMT. Eur Rev Med Pharmacol Sci. 2020;24:3686–93.

    CAS  PubMed  Google Scholar 

  23. Han GH, Lu KJ, Wang P, Ye J, Ye YY, Huang JX. LncRNA SNHG16 predicts poor prognosis in ESCC and promotes cell proliferation and invasion by regulating Wnt/beta-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2018;22:3795–803.

    PubMed  Google Scholar 

  24. Liu J, Liu ZX, Wu QN, Lu YX, Wong CW, Miao L, Wang Y, Wang Z, Jin Y, He MM, Ren C, Wang DS, Chen DL, Pu HY, Feng L, Li B, Xie D, Zeng MS, Huang P, Lin A, Lin D, Xu RH, Ju HQ. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020;11:1507.

    Article  CAS  Google Scholar 

  25. Lin C, Zhang S, Wang Y, Wang Y, Nice E, Guo C, Zhang E, Yu L, Li M, Liu C, Hu L, Hao J, Qi W, Xu H. Functional role of a novel long noncoding RNA TTN-AS1 in esophageal squamous cell carcinoma progression and metastasis. Clin Cancer Res. 2018;24:486–98.

    Article  CAS  Google Scholar 

  26. Zhang Y, Zhang L, Wang R, Wang B, Hua P, Li J. LncRNA Erbb4-IR promotes esophageal squamous cell carcinoma (ESCC) by downregulating miR-145. J Cell Biochem. 2019;120:17566–72.

    Article  CAS  Google Scholar 

  27. Chen W, Sun SG, Jiang MX, Li SS, Yuan K. [FOXD2-AS1 is corelated with clinicopathological parameter of laryngeal carcinoma and promote cancer cell proliferation]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2019;33:436–40.

    CAS  PubMed  Google Scholar 

  28. Zhang M, Jiang X, Jiang S, Guo Z, Zhou Q, He J. LncRNA FOXD2-AS1 regulates miR-25-3p/Sema4c axis to promote the invasion and migration of colorectal cancer cells. Cancer Manag Res. 2019;11:10633–9.

    Article  CAS  Google Scholar 

  29. Zhao T, Zhang J, Ye C, Tian L, Li Y. lncRNA FOXD2-AS1 promotes hemangioma progression through the miR-324-3p/PDRG1 pathway. Cancer Cell Int. 2020;20:189.

    Article  Google Scholar 

  30. Chen DZ, Wang TF, Dai WC, Xu X, Chen PF. LncRNA FOXD2-AS1 accelerates the progression of cervical cancer via downregulating CDX1. Eur Rev Med Pharmacol Sci. 2019;23:10234–40.

    PubMed  Google Scholar 

  31. Liu X, Fu Q, Li S, Liang N, Li F, Li C, Sui C, Dionigi G, Sun H. LncRNA FOXD2-AS1 functions as a competing endogenous RNA to regulate TERT expression by sponging miR-7-5p in thyroid cancer. Front Endocrinol (Lausanne). 2019;10:207.

    Article  Google Scholar 

  32. Hu W, Feng H, Xu X, Huang X, Huang X, Chen W, Hao L, Xia W. Long noncoding RNA FOXD2-AS1 aggravates hepatocellular carcinoma tumorigenesis by regulating the miR-206/MAP3K1 axis. Cancer Med. 2020;9:5620–31.

    Article  CAS  Google Scholar 

  33. Chen Z, Zhang Z, Zhao D, Feng W, Meng F, Han S, Lin B, Shi X. Long noncoding RNA (lncRNA) FOXD2-AS1 promotes cell proliferation and metastasis in hepatocellular carcinoma by regulating MiR-185/AKT axis. Med Sci Monit. 2019;25:9618–29.

    Article  CAS  Google Scholar 

  34. An Q, Zhou L, Xu N. Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143. Biomed Pharmacother. 2018;103:415–20.

    Article  CAS  Google Scholar 

  35. Chen G, Sun W, Hua X, Zeng W, Yang L. Long non-coding RNA FOXD2-AS1 aggravates nasopharyngeal carcinoma carcinogenesis by modulating miR-363-5p/S100A1 pathway. Gene. 2018;645:76–84.

    Article  CAS  Google Scholar 

  36. Guo J, Zhao P, Liu Z, Li Z, Yuan Y, Zhang X, Yu Z, Fang J, Xiao K. MiR-204-3p inhibited the proliferation of bladder cancer cells via modulating lactate dehydrogenase-mediated glycolysis. Front Oncol. 2019;9:1242.

    Article  Google Scholar 

  37. Xi X, Teng M, Zhang L, Xia L, Chen J, Cui Z. MicroRNA-204-3p represses colon cancer cells proliferation, migration, and invasion by targeting HMGA2. J Cell Physiol. 2020;235:1330–8.

    Article  CAS  Google Scholar 

  38. Zhou Y, Yin L, Li H, Liu LH, Xiao T. The LncRNA LINC00963 facilitates osteosarcoma proliferation and invasion by suppressing miR-204-3p/FN1 axis. Cancer Biol Ther. 2019;20:1141–8.

    Article  CAS  Google Scholar 

Download references

Funding

This work was supported by State Key Laboratory of Pathogenesis, Prevention and Treatment of Central Asian High Incidence Diseases Fund (SKL-HIDCA-2020-13).

Author information

Authors and Affiliations

  1. Department of Thoracic Surgery, Affiliated Tumor Hospital of Xinjiang Medical University, Suzhou Street 789, Ürümqi, 830011, China

    Dongbo Luo, Adili Salai, Hongbo Lv, Yang Wang & Yunfei Gao

Authors
  1. Dongbo Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adili Salai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hongbo Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yunfei Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DL conceived and designed the study, and drafted the manuscript. AS and HL collected, analyzed and interpreted the experimental data. YW and YG revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Dongbo Luo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures involving human participants were performed in accordance with the ethical standards of the Institutional and National Research Committee, and with the Declaration of Helsinki. Ethical approval was obtained from the Ethical Committee of the Affiliated Tumor Hospital of Xinjiang Medical University.

Informed consent

Subjects signed the informed consent.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

12094_2022_2850_MOESM1_ESM.pdf

Fig. S1 The correlation between progression-free survival and FOXD2-AS1 expression was detected by bioinformatic analysis (PDF 40 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Luo, D., Salai, A., Lv, H. et al. FOXD2-AS1 acts an oncogene in esophageal squamous cell carcinoma through sponging miR-204-3p. Clin Transl Oncol 24, 1954–1963 (2022). https://doi.org/10.1007/s12094-022-02850-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-022-02850-7

Keywords

Search

Navigation